Filters
Custom request?
Type
Production region
Qualifications
Country of origin
Vecuronium API Manufacturers & Suppliers
3 verified results
All Vecuronium data. Full access. Full negotiation power
Commercial-scale Suppliers
All certificates
All certificates
Employees: 3,500+
All certificates
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Vecuronium | CAS No: 86029-43-8 | GMP-certified suppliers
A medication that provides controlled skeletal muscle relaxation as an adjunct to general anesthesia, supporting neuromuscular blockade during surgical procedures.
Therapeutic categories
Primary indications
- Vecuronium is a muscle relaxing agent and is used as an adjunct in general anesthesia
Product Snapshot
- Vecuronium is an injectable small molecule formulated as lyophilized powder and solution for parenteral administration
- It is primarily used as a muscle relaxant adjunct during general anesthesia
- Vecuronium is approved for use in the US and Canada markets with some investigational applications
Clinical Overview
Pharmacodynamically, vecuronium exerts its effects through competitive antagonism at nicotinic acetylcholine receptors located at the motor end plates of skeletal muscle. By binding to these cholinergic receptors without activating them, vecuronium inhibits acetylcholine from triggering postsynaptic depolarization, thereby preventing calcium release and subsequent muscle contraction. This mechanism allows controlled muscle relaxation during surgical procedures requiring neuromuscular blockade.
Vecuronium’s pharmacokinetic properties include hepatic metabolism with partial biliary and renal excretion. Unlike some neuromuscular blockers, it does not rely heavily on renal elimination, which makes it potentially suitable for patients with compromised kidney function. The agent has a generally intermediate duration of action and is readily reversible with acetylcholinesterase inhibitors.
From a safety and toxicity standpoint, vecuronium is characterized by minimal cardiovascular effects, a notable advantage over related compounds such as pancuronium, which has pronounced vagolytic activity. However, as with other neuromuscular blocking agents, it requires careful dosing and monitoring to avoid prolonged paralysis and respiratory complications. Hypersensitivity reactions have been reported but are uncommon.
Vecuronium is available under various trade names globally and remains a standard agent in operating rooms for muscle relaxation, especially when rapid recovery of neuromuscular function is desired.
When sourcing vecuronium active pharmaceutical ingredient (API), attention should be given to compliance with pharmacopeial standards, batch-to-batch consistency, and purity profiles to ensure safe formulation. Thorough supplier qualification and verification of manufacturing controls are critical to mitigate risks associated with impurities or variability in steroid ester raw materials.
Identification & chemistry
| Generic name | Vecuronium |
|---|---|
| Molecule type | Small molecule |
| CAS | 86029-43-8 |
| UNII | 5438723848 |
| DrugBank ID | DB01339 |
Pharmacology
| Summary | Vecuronium is a bisquaternary ammonium compound that acts as a competitive antagonist at nicotinic acetylcholine receptors, specifically targeting the neuronal acetylcholine receptor subunit alpha-2. By inhibiting acetylcholine binding at the motor end plate, it prevents depolarization and subsequent muscle contraction. This mechanism underlies its use as a muscle relaxant adjunct during general anesthesia. |
|---|---|
| Mechanism of action | Vecuronium is a bisquaternary nitrogen compound that acts by competitively binding to nicotinic cholinergic receptors. The binding of vecuronium decreases the opportunity for acetylcholine to bind to the nicotinic receptor at the postjunctional membrane of the myoneural junction. As a result, depolarization is prevented, calcium ions are not released and muscle contraction does not occur. |
| Pharmacodynamics | The principal pharmacologic effects demonstrated by vecuronium revolve around its competitive binding of cholinergic receptors located at motor end plates. This competitive binding results in muscle relaxant effects that are typically employed as an adjunct to general anesthesia. |
Targets
| Target | Organism | Actions |
|---|---|---|
| Neuronal acetylcholine receptor subunit alpha-2 | Humans | antagonist |
ADME / PK
| Half-life | 51–80 minutes |
|---|---|
| Metabolism | 100% |
| Route of elimination | Fecal (40-75%) and renal (30% as unchanged drug and metabolites) |
Formulation & handling
- Vecuronium is primarily formulated for intravenous injection as a lyophilized powder or solution due to low oral bioavailability.
- As a small molecule steroid ester, it exhibits low water solubility, requiring careful consideration of solubilization in parenteral formulations.
- Handling should account for light and temperature sensitivity to maintain stability of lyophilized and solution forms.
Regulatory status
| Lifecycle | The active pharmaceutical ingredient (API) is currently marketed in the US and Canada with primary patents expired, allowing for generic competition and established market availability. Ongoing regulatory approvals support its continued presence in these mature pharmaceutical markets. |
|---|
| Markets | US, Canada |
|---|
Supply Chain
| Supply chain summary | Vecuronium's manufacturing and supply landscape includes several originator and generic companies involved primarily in packaging and distribution. Branded products such as Norcuron have a presence mainly in the US and Canadian markets. Patent expirations have facilitated established generic competition from multiple manufacturers. |
|---|
Vecuronium is a type of Neuromuscular blocking agents
Neuromuscular blocking agents (NMBAs) belong to a vital category of pharmaceutical active pharmaceutical ingredients (APIs) used in the field of medicine. These agents play a crucial role in the neuromuscular blockade, a pharmacological state that inhibits the transmission of nerve impulses at the neuromuscular junction. By doing so, NMBAs induce temporary paralysis in skeletal muscles, making them indispensable in various medical procedures and surgical interventions.
NMBAs work by targeting the neuromuscular junction, where motor neurons communicate with skeletal muscle fibers. They achieve this by interfering with the transmission of acetylcholine, a neurotransmitter responsible for signaling muscle contraction. By blocking the action of acetylcholine, NMBAs prevent muscle movement and promote muscle relaxation, allowing surgeons to perform intricate procedures more effectively.
These pharmaceutical APIs are extensively used during surgeries requiring muscle relaxation, such as abdominal surgeries, orthopedic procedures, and endotracheal intubation. Furthermore, NMBAs find application in critical care settings, assisting in mechanical ventilation and facilitating optimal patient-ventilator synchronization.
It is worth mentioning that the usage of NMBAs necessitates close monitoring and expertise, as their administration requires precise dosing and careful titration to maintain the desired level of muscle relaxation while avoiding excessive paralysis. Anesthesia professionals and intensivists meticulously administer these agents, taking into consideration factors such as patient age, weight, and individual response.
In conclusion, Neuromuscular blocking agents are an essential API category within the pharmaceutical industry, vital for achieving muscle relaxation during surgical procedures and critical care management. Their precise and skillful utilization significantly contributes to the success of medical interventions and patient outcomes.
Vecuronium API manufacturers & distributors
Compare qualified Vecuronium API suppliers worldwide. We currently have 3 companies offering Vecuronium API, with manufacturing taking place in 3 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.
| Supplier | Type | Country | Product origin | Certifications | Portfolio |
|---|---|---|---|---|---|
| Curia | Producer | United States | United States | CoA, EDMF/ASMF, GMP, JDMF, MSDS, USDMF | 106 products |
| Euticals | Producer | Italy | Unknown | CoA, JDMF, USDMF | 48 products |
| Zhejiang Xianju | Producer | China | China | CoA, USDMF | 17 products |
When sending a request, specify which Vecuronium API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).
Use the list above to find high-quality Vecuronium API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.
